{"id":"W218989274","doi":"10.1182/blood.v124.21.5544.5544","title":"Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: 60-Month Update of a Phase 1/2 Study","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Medicine; Internal medicine; Gastroenterology; Imatinib; Dasatinib; Imatinib mesylate; Discontinuation; Nilotinib; Myeloid leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00186336,0.0004394689,0.00116724,0.0002886395,0.0001883199,0.0007450453,0.0002652156,0.0004669813,0.001042559],"category_scores_gemma":[0.0008173493,0.000207198,0.0008782847,0.0003968607,0.0001808795,0.0004262172,0.0002132662,0.001091886,0.000238298],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003729298,"about_ca_system_score_gemma":0.0004871571,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005439773,"about_ca_topic_score_gemma":0.001971906,"domain_scores_codex":[0.9996148,0.0001939713,0.00003788609,0.00004293188,0.00005869307,0.0000516403],"domain_scores_gemma":[0.9994332,0.0001218257,0.0001734746,0.00002593696,0.00005429886,0.0001911606],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3170367,0.01725332,0.1279115,0.00245972,0.004035843,0.0008709324,0.0005613233,0.002429478,0.04173406,0.0002576839,0.01002013,0.4754293],"study_design_scores_gemma":[0.2226489,0.4045484,0.3377231,0.0003782361,0.003998015,0.001967316,0.0002774769,0.003551924,0.006201162,0.0001780388,0.01845049,0.00007692596],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9827335,0.01413312,0.0002261676,0.000378796,0.00008810862,0.0004398546,0.0007550729,0.00003216791,0.001213236],"genre_scores_gemma":[0.9886032,0.007329176,0.0005153089,0.000755031,0.0002121337,0.0003402034,0.001625687,0.000008554939,0.0006106817],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00186336,"threshold_uncertainty_score":0.009854496,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0146167909784973,"score_gpt":0.2975442278803948,"score_spread":0.2829274369018975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}